3 signs shares in ResMed Inc are a long-term bargain

Shares in ResMed have been falling, here are three signs that now is a great time to buy.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in breathing device maker ResMed Inc. (ASX: RMD) are down nearly 9% so far in 2014, compared to a minor 0.8% increase in the S&P / ASX 200 Index (Index: ^AXJO) (ASX: XJO).

In my view this weakness could be a great opportunity to buy or top up on ResMed shares which could turn out to be a long-term bargain. Here are three reasons why:

1. ResMed is still buying its own shares

Last week ResMed's board of directors approved a new share buyback program granting the company approval to repurchase up to 20 million shares on the open market. This represents around 14% of outstanding shares and is a continuation of the company's long-term capital management plan.

The impact of the program is to increases earnings per share, as well as the company's share price. ResMed holds around U.S. $876 million in cash and cash equivalents and it can be an effective way to return some of that cash to shareholders.

2. It could be cheaper than its competitor

With a price-to-earnings (p/e) ratio of around 20, at a high level ResMed appears to offer better current value than Kiwi competitor, Fisher & Paykel Healthcare Limited (ASX: FPH), with a comparatively high p/e ratio of 27.

Obviously this fails to take into account expected growth and last month FPH announced an increase to expected net profit for the full year. However ResMed has grown net profit by 35% in the last three years and this is likely to continue per reason three below.

3. Long-term demographics are in its favour

A global increase in the 'greying population', rising obesity and increasing global healthcare spending will help to play into the hands of ResMed in the years to come.

Mick Farrell, ResMed's chief executive officer, noted in the company's recent quarterly update the strong prospects for growth from new product launches: "Opportunities for growth remain in sleep, respiratory care, and cardiorespiratory markets in all geographies."

Foolish takeaway

Behind ResMed's falling price is a company with strong long-term growth prospects and a capital management plan to return value to shareholders. If revenue and earnings growth can continue, the current price could turn out to be a long-term bargain.

Motley Fool contributor Regan Pearson does not own shares in any of the companies mentioned in this article.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »